-
Teva believes its generic version of Mylan's EpiPen will capture 25 percent of the US market by the end of the year, as reported Yahoo!Finance Tuesday.
-
Analysts previously estimated that the generic drug could boost Teva's annual revenue for $250 million and earnings per share by $0.04 to $0.06.
-
According to CEO Kare Schultz, Teva has introduced the adult version of the therapy, while the paediatric version will be unveiled later this year.
-
Meanwhile, many pharmacy chains and distributors have to receive supplies of Teva's generic version of EpiPen.
-
The news comes as Mylan's product has been in short supply due to manufacturing issues at a Pfizer facility that produces the auto-injection device.
-
Teva's generic version of EpiPen was approved by the FDA last August after several years of delay.
-
FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>
To read more NewsPoints articles, click here.
